NCT02525692 - Oral ONC201 in Adult Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

April 17, 2023

Study Completion Date

April 17, 2023

Conditions

GlioblastomaDiffuse Midline GliomaH3 K27M GliomaThalamic GliomaInfratentorial GliomaBasal Ganglia Glioma

Interventions

DRUG

Dordaviprone (ONC201)

Dordaviprone (ONC201) is a brain-penetrant, small-molecule imipridone that acts as a mitochondrial caseinolytic protease P (ClpP) agonist and a dopamine receptor D2 (DRD2) antagonist.

Trial Locations (5)

33176

Miami Cancer Institute, Miami

84112

University of Utah, Huntsman Cancer Institute, Salt Lake City

90024

University of California, Los Angeles, Los Angeles

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston